Pulmonary Hypertension Research Study
|
Inhaled Nitric Oxide and Sildenafil Study
|
Individuals who have sickle cell disease and pulmonary hypertension (increased blood pressure in the lungs) sometimes have more complications (shortness of breath, pain crises, pneumonia, and death). Because of this increased risk, this clinical trial will evaluate if experimental treatments for high blood pressure in the lungs can lower pressures in the lungs and reduce the likelihood of complications. The study has three parts.
The first part involves a thorough screening of your heart and lungs. These tests will be performed on an outpatient or inpatient basis. The second part is specialized testing at the Clinical Center, during which blood pressure in the blood vessels going to your lungs (pulmonary artery) will be measured. The third part of the study is for experimental treament, during which the drug sildenafil will be combined with inhaled nitric oxide gas for 6 weeks. This can be done as either an inpatient or outpatient and you must have been taking sildenafil for 3 months and still have high blood pressure in the lungs.
For more information, please contact study coordinators, Lori Hunter or Wynona Coles at 301-435-2345 or email VascularStudy@nhlbi.nih.gov
|
|
|
|
Protocol Information |
|
|
Disease and Treatment Information |
|
|
Support Groups |
|
|
|
|
Pulmonary Hypertension Research Study
|
Pulmonary Hypertension - Research Screening Study
|
Researchers at the NIH invite you to take part in a study that will help us learn how often people with sickle cell anemia develop a complication called pulmonary hypertension. Pulmonary hypertension is a serious disease in which blood pressure in the artery to the lungs is elevated.
You are eligible to participate if you are 18 years of age or older and have sickle cell disease. This study consists of an initial evaluation (including a physical exam, blood tests, and an echocardiogram), a follow-up telephone interview every year after the initial echocardiogram, and a repeat echocardiogram and blood tests approximately two years after the first. There is no cost to participate.
Please contact the study coordinator at 301-402-2104 for more information or email VascularStudy@nhlbi.nih.gov
|
|
|
|
Protocol Information |
|
|
Disease and Treatment Information |
|
|
Support Groups |
|
|
|
|
Pulmonary Hypertension Research Study
|
walk-PHaSST Pulmonary Hypertension Trial
|
This clinical research study will test the ability of the drug, sildenafil, to decrease elevated blood pressure in the pulmonary artery (the blood vessel that leads from the heart to the lungs).
You may be eligible to participate in this study if you are over the age of 12 and have sickle cell disease and symptoms or lung tests indicating that the blood pressure in your pulmonary (lungs) artery may be elevated. This condition is called pulmonary hypertension. Pulmonary hypertension can cause fatigue, dizziness, and shortness of breath because the blood vessels that supply the lungs narrow, forcing the heart to work harder to push blood through. For more information please contact Wynona Coles at 301-435-2345 or email LungStudy@nhlbi.nih.gov
|
|
|
|
Disease and Treatment Information |
|
|
|
|
|